Full Press Release Details
Investor Contact: Katy Grissom (317) 273-9248 kathryn.grissom@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com
Elanco Completes Sale of Aqua Business
Transaction concentrates Elanco's focus
on significant value creation opportunities and accelerates deleveraging progress
GREENFIELD, Ind. (July 9, 2024) - Elanco Animal Health
Incorporated (NYSE: ELAN) announced today it has completed the divestiture of its aqua business to Merck Animal Health (NYSE: MRK) for
approximately $1.3 billion in cash, with approximately $1.05-$1.1 billion in net proceeds available for debt paydown in the third quarter
"Finalizing this transaction marks a significant milestone in
concentrating our focus on high-value opportunities in pet health and livestock sustainability while creating balance sheet flexibility.
Elanco's positive trajectory, demonstrated by three consecutive quarters of underlying revenue growth, pipeline progress, and our ability
to reduce debt, strengthens our value proposition," said Todd Young, Executive Vice President and CFO of Elanco Animal Health.
"The proceeds from this transaction, combined with increased free cash flow from our operations, accelerates our deleveraging and
positions us to deliver substantial value over time."
The successful completion of this transaction enables the company to
pay down term loan debt on a pro-rata basis per the terms of the company's credit agreements. Combined with the expected $280 million
to $320 million of cash generated from the base business, the company expects to pay down approximately $1.3 to $1.4 billion of debt in
2024, ending the year with net debt to adjusted EBITDA in the mid-4x range. Net debt to adjusted EBITDA is projected to improve further
in 2025 to the high-3x to low-4x range. The company will provide additional information about the transaction's impact on its 2024
financial outlook during the second quarter earnings call in August.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader
in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets,
creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage,
we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local
and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose-
all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning
of the federal securities laws. These forward-looking statements include, without limitation, statements regarding the expected financial
impacts of the divestiture, plans for using the cash we receive in the divestiture, the impact of the divestiture on our business and
financial results, and expected financial results for 2024 and 2025. There are a number of important factors that could cause actual events
to differ materially from those suggested or indicated by such forward-looking statements, including our ability to recognize the expected
financial and cash generation benefits of the transaction; the impact of disruptive innovations and advances in veterinary medical practices,
animal health technologies and alternatives to animal-derived protein; changes in regulatory restrictions on the use of antibiotics in
farm animals; the success of our research and development and licensing efforts; unanticipated safety, quality of efficacy concerns and
the impact of identified concerns associated with our products; the lack of availability or significant increases in the cost of raw materials;
risks related to the evaluation of animals; manufacturing problems and capacity imbalances; and actions by regulatory bodies, including
as a result of their interpretation of studies on product safety. For information about other factors that could cause actual results
to differ materially from forward-looking statements, please see the company's latest Form 10-K and Form 10-Qs filed with
the Securities and Exchange Commission. Although we have attempted to identify important risk factors, there may be other risk factors
not presently known to us or that we presently believe are not material that could cause actual results and developments to differ materially
from those made in or suggested by the forward-looking statements contained in this press release. We caution you against relying on any
forward-looking statements, which should also be read in conjunction with the other cautionary statements that are included elsewhere
in this press release. Any forward-looking statement made by us in this press release speaks only as of the date thereof. Factors or events
that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake
no obligation to publicly update or to revise any forward-looking statement, whether as a result of new information, future developments
or otherwise, except as may be required by law.